HC Wainwright Forecasts Alumis' Q1 Earnings (NASDAQ:ALMS)

Alumis Inc. (NASDAQ:ALMS - Free Report) - Investment analysts at HC Wainwright raised their Q1 2025 EPS estimates for Alumis in a report issued on Wednesday, March 26th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($1.07) for the quarter, up from their prior estimate of ($1.29). HC Wainwright currently has a "Buy" rating and a $15.00 target price on the stock. The consensus estimate for Alumis' current full-year earnings is ($8.51) per share. HC Wainwright also issued estimates for Alumis' Q2 2025 earnings at ($0.81) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.78) EPS and FY2025 earnings at ($3.39) EPS.

A number of other research firms also recently issued reports on ALMS. Oppenheimer started coverage on Alumis in a research report on Thursday, January 30th. They set an "outperform" rating and a $32.00 price target on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of Alumis in a report on Thursday, March 20th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $26.00.

Alumis Trading Up 11.7 %

ALMS traded up $0.72 during trading on Friday, hitting $6.86. 708,984 shares of the stock were exchanged, compared to its average volume of 290,394. The firm has a 50 day simple moving average of $5.36 and a 200 day simple moving average of $8.26. Alumis has a 1 year low of $3.18 and a 1 year high of $13.53.

Remove Ads

Institutional Trading of Alumis

A number of institutional investors have recently modified their holdings of ALMS. Foresite Capital Management V LLC raised its stake in shares of Alumis by 3.5% during the 4th quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company's stock worth $45,426,000 after acquiring an additional 194,459 shares in the last quarter. Foresite Capital Management VI LLC acquired a new position in shares of Alumis during the fourth quarter worth $33,033,000. Samsara BioCapital LLC purchased a new stake in shares of Alumis during the 3rd quarter valued at $34,886,000. Tang Capital Management LLC boosted its position in shares of Alumis by 40.6% in the 4th quarter. Tang Capital Management LLC now owns 600,000 shares of the company's stock worth $4,716,000 after purchasing an additional 173,406 shares in the last quarter. Finally, Ally Bridge Group NY LLC grew its stake in Alumis by 6.4% during the 4th quarter. Ally Bridge Group NY LLC now owns 445,259 shares of the company's stock worth $3,500,000 after buying an additional 26,843 shares during the last quarter.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.